Wilmington Health Family Medicine
Welcome,         Profile    Billing    Logout  
 1 Trial 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Appel, James
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

Active, not recruiting
3
80
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
05/24
12/24
ADAMANT, NCT05932654: POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis

Completed
2
22
US
BSI-045B
Biosion, Inc.
Atopic Dermatitis
09/24
09/24
Weiss, Eduardo
ADapt, NCT05369403: A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

Active, not recruiting
3
120
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
01/24
12/24
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

Active, not recruiting
3
80
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
05/24
12/24
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Recruiting
3
250
US
Ixekizumab, LY2439821, Tirzepatide, LY3298176
Eli Lilly and Company
Psoriasis, Obesity
12/25
05/26
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Recruiting
3
595
Europe, Canada, Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company
Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
09/24
08/29
TONE, NCT05971381: Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells

Active, not recruiting
N/A
109
US
RECELL® Autologous Cell Harvesting Device, Spray-On SkinTM Cells
Avita Medical
Vitiligo
07/24
01/25
NCT05323253: A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma

Recruiting
N/A
86
Canada, US, RoW
DaRT seeds, DaRT
Alpha Tau Medical LTD.
Recurrent Squamous Cell Carcinoma
12/24
12/25

Download Options